Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of two 20 mg rabeprazole sodium gastro-resistant tablet formulations under fasting in healthy Thai subjects
TCTR20221104001Phase 1Unknown
- Sponsor
- Korea United Pharm Inc.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of rabeprazole in gastroesophageal reflux disease (GERD) and Peptic ulcer disease (PUD) (2 arms), sponsored by Korea United Pharm Inc. Primary endpoint: Primary pharmacokinetic endpoints. Status: unknown.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on TCTR20221104001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221104001.